X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3494) 3494
Publication (280) 280
Newsletter (34) 34
Book Review (33) 33
Book Chapter (8) 8
Newspaper Article (8) 8
Conference Proceeding (3) 3
Magazine Article (3) 3
Transcript (2) 2
Dissertation (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
capecitabine (3063) 3063
humans (3020) 3020
female (2360) 2360
oncology (2239) 2239
middle aged (2023) 2023
index medicus (2004) 2004
aged (1949) 1949
deoxycytidine - analogs & derivatives (1866) 1866
fluorouracil - analogs & derivatives (1692) 1692
male (1686) 1686
chemotherapy (1610) 1610
adult (1572) 1572
antineoplastic combined chemotherapy protocols - therapeutic use (1467) 1467
deoxycytidine - administration & dosage (1315) 1315
antineoplastic combined chemotherapy protocols - adverse effects (1259) 1259
fluorouracil - administration & dosage (1239) 1239
cancer (1148) 1148
deoxycytidine - adverse effects (1134) 1134
treatment outcome (1098) 1098
fluorouracil - adverse effects (1016) 1016
breast neoplasms - drug therapy (762) 762
care and treatment (699) 699
fluorouracil (698) 698
oxaliplatin (670) 670
aged, 80 and over (650) 650
5-fluorouracil (648) 648
disease-free survival (629) 629
therapy (627) 627
antimetabolites, antineoplastic - adverse effects (622) 622
metastasis (615) 615
colorectal cancer (581) 581
colorectal neoplasms - drug therapy (579) 579
breast cancer (578) 578
deoxycytidine - therapeutic use (567) 567
pharmacology & pharmacy (560) 560
research (514) 514
neoplasm metastasis (505) 505
drug administration schedule (504) 504
organoplatinum compounds - administration & dosage (502) 502
trial (497) 497
antineoplastic combined chemotherapy protocols - administration & dosage (494) 494
fluorouracil - therapeutic use (483) 483
breast neoplasms - pathology (458) 458
neoplasm staging (441) 441
medicine & public health (424) 424
drug therapy (418) 418
survival (414) 414
bevacizumab (411) 411
antimetabolites, antineoplastic - therapeutic use (410) 410
clinical trials (404) 404
combination (398) 398
adenocarcinoma - drug therapy (384) 384
leucovorin (363) 363
antimetabolites, antineoplastic - administration & dosage (361) 361
toxicity (353) 353
retrospective studies (342) 342
1st-line treatment (339) 339
colorectal neoplasms - pathology (337) 337
cisplatin (332) 332
antineoplastic agents (330) 330
survival analysis (328) 328
docetaxel (327) 327
stomach neoplasms - drug therapy (324) 324
antineoplastic agents - therapeutic use (322) 322
antineoplastic agents - adverse effects (321) 321
cancer research (316) 316
antimitotic agents (312) 312
cancer therapies (304) 304
carcinoma (302) 302
administration, oral (301) 301
irinotecan (298) 298
hematology, oncology and palliative medicine (296) 296
organoplatinum compounds - adverse effects (294) 294
capecitabine - administration & dosage (289) 289
gemcitabine (288) 288
radiotherapy (283) 283
dose-response relationship, drug (282) 282
health aspects (276) 276
kaplan-meier estimate (275) 275
phase-ii (268) 268
paclitaxel (266) 266
patients (265) 265
survival rate (263) 263
disease progression (261) 261
camptothecin - analogs & derivatives (260) 260
oral capecitabine (260) 260
metastatic colorectal-cancer (258) 258
pharmacology/toxicology (256) 256
taxoids - administration & dosage (254) 254
capecitabine - adverse effects (253) 253
cancer patients (251) 251
surgery (243) 243
tumors (243) 243
analysis (242) 242
oncology, experimental (237) 237
dosage and administration (234) 234
phase-ii trial (230) 230
adenocarcinoma (229) 229
leucovorin - administration & dosage (229) 229
efficacy (228) 228
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3372) 3372
Japanese (43) 43
Chinese (33) 33
French (27) 27
German (18) 18
Spanish (16) 16
Russian (10) 10
Dutch (9) 9
Italian (5) 5
Korean (4) 4
Hungarian (3) 3
Danish (2) 2
Polish (2) 2
Czech (1) 1
Finnish (1) 1
Hebrew (1) 1
Portuguese (1) 1
Romanian (1) 1
Serbian (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, ISSN 0446-6586, 2018, Volume 115, Issue 3, p. 290
We report the case of a 61-year-old man who experienced severe adverse effects of capecitabine because of dihydropyrimidine dehydrogenase (DPD) deficiency. In... 
Antimetabolites, Antineoplastic - therapeutic use | Dihydropyrimidine Dehydrogenase Deficiency - diagnosis | Capecitabine - adverse effects | Humans | Middle Aged | Antimetabolites, Antineoplastic - adverse effects | Male | Capecitabine - therapeutic use | Fluorouracil
Journal Article
by Zhang, JT and Fu, FM and Lin, YX and Chen, YZ and Lu, MJ and Chen, MY and Yang, PD and Huang, M and Wang, C
ONCOTARGET, ISSN 1949-2553, 10/2017, Volume 8, Issue 46, pp. 81636 - 81648
Capecitabine in addition to anthracycline-taxane based regimens for patients with early breast cancer (EBC) has been reported in previous clinical trials, but... 
early breast cancer | side-effects | SURGICAL ADJUVANT BREAST | DOXORUBICIN PLUS CYCLOPHOSPHAMIDE | BEVACIZUMAB | COMBINATION THERAPY | PHASE-III | DOCETAXEL | PACLITAXEL | CELL BIOLOGY | capecitabine | EPIRUBICIN | disease-free survival | NEOADJUVANT CHEMOTHERAPY | overall survival | THYMIDINE PHOSPHORYLASE
Journal Article
Clinical Breast Cancer, ISSN 1526-8209, 2011, Volume 11, Issue 6, pp. 349 - 356
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 04/2008, Volume 26, Issue 12, pp. 2013 - 2019
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 1, pp. 64 - 71
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 13, pp. 1355 - 1369
Journal Article
JNCCN Journal of the National Comprehensive Cancer Network, ISSN 1540-1405, 07/2014, Volume 12, Issue 7, pp. 1028 - 1059
The NCCN Guidelines for Colon Cancer address diagnosis, pathologic staging, surgical management, perioperative treatment, posttreatment surveillance,... 
PHASE-III TRIAL | GROWTH-FACTOR RECEPTOR | UNRESECTABLE LIVER METASTASES | BEVACIZUMAB-CONTAINING ARMS | ONCOLOGY | HIGH-DOSE LEUCOVORIN | POSTPROGRESSION SURVIVAL-TIME | 1ST-LINE COMBINATION CHEMOTHERAPY | KRAS WILD-TYPE | CAPECITABINE PLUS OXALIPLATIN | METASTATIC COLORECTAL-CANCER | ras Proteins - genetics | Proto-Oncogene Proteins p21(ras) | Colonic Neoplasms - drug therapy | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Antineoplastic Agents - therapeutic use | Bevacizumab | Colonic Neoplasms - surgery | Fluorouracil - therapeutic use | Deoxycytidine - therapeutic use | Leucovorin - adverse effects | Fluorouracil - adverse effects | Antineoplastic Agents - adverse effects | Angiogenesis Inhibitors - therapeutic use | Deoxycytidine - adverse effects | Leucovorin - therapeutic use | Cetuximab | Liver Neoplasms - secondary | Angiogenesis Inhibitors - adverse effects | Camptothecin - analogs & derivatives | Antibodies, Monoclonal, Humanized - adverse effects | Camptothecin - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Camptothecin - therapeutic use | Fluorouracil - analogs & derivatives | Membrane Proteins - genetics | Liver Neoplasms - drug therapy | Liver Neoplasms - surgery | Proto-Oncogene Proteins - genetics | Treatment Outcome | Disease Progression | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | GTP Phosphohydrolases - genetics | Proto-Oncogene Proteins B-raf - genetics | Colonic Neoplasms - pathology | Organoplatinum Compounds - therapeutic use | Deoxycytidine - analogs & derivatives | Organoplatinum Compounds - adverse effects
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 9, pp. 1007 - 1018
Summary Background Dysregulation of the hepatocyte growth factor (HGF)/MET pathway promotes tumour growth and metastasis. Rilotumumab is a fully human,... 
Hematology, Oncology and Palliative Medicine | AMPLIFICATION | PHARMACOKINETICS | ONCOLOGY | HEPATOCYTE GROWTH-FACTOR | C-MET | MONOCLONAL-ANTIBODY | CIRCULATING LEVEL | AMG 102 | CANCER | EXPRESSION | CARCINOMA | Confidence Intervals | Adenocarcinoma - pathology | Esophagogastric Junction - drug effects | Prognosis | Capecitabine | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Antibodies, Monoclonal - therapeutic use | Male | Stomach Neoplasms - pathology | Dose-Response Relationship, Drug | Fluorouracil - therapeutic use | Deoxycytidine - therapeutic use | Fluorouracil - adverse effects | Neoplasm Invasiveness - pathology | Adult | Deoxycytidine - adverse effects | Female | Double-Blind Method | Drug Administration Schedule | Fluorouracil - analogs & derivatives | Proportional Hazards Models | Esophagogastric Junction - pathology | Survival Rate | Treatment Outcome | Stomach Neoplasms - drug therapy | Adenocarcinoma - drug therapy | Disease-Free Survival | Maximum Tolerated Dose | Cisplatin - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Cisplatin - adverse effects | Epirubicin - therapeutic use | Aged | Neoplasm Staging | Stomach Neoplasms - mortality | Deoxycytidine - analogs & derivatives | Adenocarcinoma - mortality | Epirubicin - adverse effects | Monoclonal antibodies | Anthracyclines | Index Medicus
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2009, Volume 360, Issue 20, pp. 2055 - 2065
This trial compared standard multiagent chemotherapy with a single agent (capecitabine) as adjuvant therapy for breast cancer in women 65 years of age or... 
SURVIVAL | TRIAL | MEDICINE, GENERAL & INTERNAL | THERAPY | CYCLOPHOSPHAMIDE | DOXORUBICIN | FOLLOW-UP | PHASE-II | DOSE-INTENSITY | CONSENSUS RECOMMENDATIONS | AGE | Breast Neoplasms - surgery | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Capecitabine | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Receptors, Estrogen - analysis | Methotrexate - therapeutic use | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Cisplatin - administration & dosage | Fluorouracil - therapeutic use | Deoxycytidine - therapeutic use | Neoplasm Metastasis | Fluorouracil - administration & dosage | Fluorouracil - adverse effects | Chemotherapy, Adjuvant - adverse effects | Aged, 80 and over | Deoxycytidine - adverse effects | Female | Doxorubicin - administration & dosage | Fluorouracil - analogs & derivatives | Kaplan-Meier Estimate | Neoplasm Recurrence, Local | Breast Neoplasms - drug therapy | Methotrexate - adverse effects | Antimetabolites, Antineoplastic - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Antimetabolites, Antineoplastic - adverse effects | Survival Analysis | Methotrexate - administration & dosage | Aged | Neoplasm Staging | Deoxycytidine - analogs & derivatives | Evaluation | Care and treatment | Usage | Aged women | Adjuvant treatment | Breast cancer | Comparative analysis | Health aspects | Cancer | Chemotherapy | Toxicity | Leukemia | Age | Index Medicus | Abridged Index Medicus
Journal Article
Lancet, The, ISSN 0140-6736, 2017, Volume 389, Issue 10073, pp. 1011 - 1024
Summary Background The ESPAC-3 trial showed that adjuvant gemcitabine is the standard of care based on similar survival to and less toxicity than adjuvant... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | THERAPY | ADENOCARCINOMA | CHEMORADIOTHERAPY | FOLINIC ACID | MODEL | CHEMOTHERAPY | Capecitabine - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Carcinoma, Pancreatic Ductal - surgery | Antimetabolites, Antineoplastic - administration & dosage | Pancreatic Neoplasms - drug therapy | Aged, 80 and over | Adult | Carcinoma, Pancreatic Ductal - mortality | Deoxycytidine - adverse effects | Female | Pancreatic Neoplasms - mortality | Chemotherapy, Adjuvant | Deoxycytidine - administration & dosage | Pancreatic Neoplasms - surgery | Kaplan-Meier Estimate | Treatment Outcome | Carcinoma, Pancreatic Ductal - drug therapy | Capecitabine - adverse effects | Antimetabolites, Antineoplastic - adverse effects | Aged | Deoxycytidine - analogs & derivatives | Antimitotic agents | Cancer patients | Care and treatment | Pancreatic cancer | Clinical trials | Product development | Metastasis | Comparative analysis | Antineoplastic agents | Studies | Antigens | Chemotherapy | Acids | Pragmatism | Pharmaceutical industry | Cancer therapies | Abdomen | Clinical Medicine | Medical and Health Sciences | Cancer and Oncology | Klinisk medicin | Medicin och hälsovetenskap | Cancer och onkologi
Journal Article